EMA SAYS A RECENT REVIEW OF AVAILABLE SAFETY DATA HAS CONCLUDED ON AN INCREASED RISK FOR LIVER INJURY FOLLOWING TREATMENT WITH MAVENCLAD
Stock Market News
- Stock Market
- Stock Market News
- Economy
- Ema Says A Recent Review Of Available Safety Data Has Concluded On An Increased Risk For Liver Injury Following Treatment With Mavenclad